Company profile
enGene company profile
enGene is a developer of a mucosal immunotherapy platform designed to treat inflammatory bowel disease and diabetes. The company's mucosal immunotherapy platform has developed a flexible nucleotide delivery technology targeting mucosal tissues to treat numerous prevalent, chronic diseases via the induction or suppression of protein expression levels, enabling physicians and doctors to regenerate physiologic, meal-regulated insulin secretion from the gut of subjects with diabetes.
Business identity
- Website
- https://www.engene.com/
- Contact email
- [email protected]
- Phone number
- 604-221-4362
- Operating status
- Active
- Company type
- For Profit
- Employee range
- 11-50 employees
- Revenue range
- $1M-$10M
- Founded
- 1999-01-01, Year
Headquarters
- Headquarters
- Sydney Forks, Nova Scotia, Canada
- Postal code
- V6T 1Z3
- Country code
- CA
- Continent
- North America